CTEP

(redirected from Cancer Therapy Evaluation Program)
AcronymDefinition
CTEPCancer Therapy Evaluation Program
CTEPConcurrent Teacher Education Program (Canada)
CTEPChartered Trust and Estate Planner
CTEPCommunity Transportation Enhancement Program (Montana)
CTEPCommunity Technology Empowerment Project
CTEPCollaborative Teacher Education Program
CTEPCadet Training & Education Program
CTEPCounter-Terrorism Enhancement Program
CTEPContingency Training Equipment Pool
CTEPCommon Effluent Treatment Plant
CTEPCommitment To Excellence Program
Copyright 1988-2018 AcronymFinder.com, All rights reserved.
References in periodicals archive ?
Associate director of NCI's Cancer Therapy Evaluation Program, Dr Jeffrey Abrams, commented: "Until now, we've been able to recommend treatment for women with these cancers at high and low risk of recurrence, but women at intermediate risk have been uncertain about the appropriate strategy to take.
Trimble, who heads the surgery section of the National Cancer Institute's Cancer Therapy Evaluation Program. "Second, are the doctors and nurse excited about the trial that's being conducted?"
Anderson, Genetics and Developmental Biology Division, NIGMS, NIH, Bldg 45, Rm 2AS.25B, MSC 6200, Bethesda, MD 20892-6200 USA, 301-594-0943, fax: 301-480-2228, e-mail: andersor@ nigms.nih.gov; Ken Kobayashi, Cancer Therapy Evaluation Program, NCI, NIH, 6130 Executive Bird, Ste 7131, MSC 7426, Rockville, MD 20852-4907 USA, 301-496-1196, fax: 301-402-0428; e-mail: kobayashik@ctep.nci.
Jeffrey Abrams, coordinator of breast cancer trials for NCI's cancer therapy evaluation program in Bethesda, said during a discussion at the meeting.
Parkinson of NCI's Cancer Therapy Evaluation Program.
The PBTC is supported by the National Cancer Institute's Cancer Therapy Evaluation Program, which is devoted to the study of correlative tumor biology and new therapies for primary CNS tumors of childhood.
The trial is sponsored by the US National Cancer Institute through cooperative research and development agreements between the NCI's Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, and both Bristol-Myers Squibb and Exelixis.
CABOSUN, conducted by The Alliance for Clinical Trials in Oncology as part of Exelixis' collaboration with the National Cancer Institute's Cancer Therapy Evaluation Program (NCI-CTEP), met its primary endpoint demonstrating a clinically meaningful and statistically significant improvement in progression-free survival (PFS) compared with sunitinib in patients with advanced intermediate- or poor-risk RCC as determined by investigator assessment.
Full browser ?